Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Frequently asked questions
What sector does Trevena, Inc (TRVN) operate in?
Trevena, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Trevena, Inc (TRVN) current stock price?
As of the latest data, Trevena, Inc stock price is $0.01, with a previous close of $0.01.
What is Trevena, Inc (TRVN) current market capitalization?
Trevena, Inc market cap is approximately 10.37 thousand.
What is Trevena, Inc (TRVN) Earnings Per Share (EPS)?
The trailing EPS is -$48.89, and the forward EPS is -$0.90.
Does Trevena, Inc (TRVN) pay dividends?
No. Trevena, Inc does not pay a dividend.
What is Trevena, Inc (TRVN) beta (volatility) score?
Trevena, Inc has a beta of -0.531, indicating lower volatility than the overall market.
